89bio, Inc. ETNB
Institutional shares held
127 Million
78.7K
calls
979K
puts
Total value of holdings
$1.06B
$653K
calls
$8.12M
puts
Market Cap
$386M
46,484,500
Shares Out.
Institutional ownership
273.73%
# of Institutions
177
We take great care to ensure that the data presented and summarized in this overview for 89bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ETNB
View all-
Janus Henderson Group PLC London, X016.5MShares$137 Million0.07% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$118 Million1.76% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.2MShares$84.7 Million3.26% of portfolio
-
Rtw Investments, LP New York, NY7.48MShares$62.1 Million0.94% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$58.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.48MShares$53.8 Million2.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.69MShares$47.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.73MShares$39.3 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA4.33MShares$36 Million1.24% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.1MShares$34 Million0.46% of portfolio
Latest Institutional Activity in ETNB
Top Purchases
Top Sells
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Insider Transactions at ETNB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 15
2025
|
Quoc Le Nguyen |
SELL
Open market or private sale
|
Direct |
15,329
-4.46%
|
$76,645
$5.95 P/Share
|
|
Feb 17
2025
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,050
-0.33%
|
$10,500
$10.57 P/Share
|
|
Feb 17
2025
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
780
-0.29%
|
$7,800
$10.57 P/Share
|
|
Feb 17
2025
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,249
-0.38%
|
$32,490
$10.57 P/Share
|
|
Feb 17
2025
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
1,050
-0.3%
|
$10,500
$10.57 P/Share
|
|
Feb 09
2025
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,817
-1.18%
|
$41,987
$11.41 P/Share
|
|
Feb 09
2025
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
3,793
-1.09%
|
$41,723
$11.41 P/Share
|
|
Feb 09
2025
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,828
-1.4%
|
$42,108
$11.41 P/Share
|
|
Feb 09
2025
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,946
-1.02%
|
$98,406
$11.41 P/Share
|
|
Feb 01
2025
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Indirect |
8,750
+37.23%
|
$78,750
$9.6 P/Share
|
|
Feb 01
2025
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
3,338
-0.95%
|
$30,042
$9.6 P/Share
|
|
Feb 01
2025
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+18.53%
|
-
|
|
Feb 01
2025
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,338
-1.2%
|
$30,042
$9.6 P/Share
|
|
Feb 01
2025
|
Ryan Martins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+22.37%
|
-
|
|
Feb 01
2025
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,338
-1.02%
|
$30,042
$9.6 P/Share
|
|
Feb 01
2025
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+19.65%
|
-
|
|
Feb 01
2025
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,598
-1.09%
|
$86,382
$9.6 P/Share
|
|
Feb 01
2025
|
Rohan Palekar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
412,000
+21.07%
|
-
|
|
Feb 01
2025
|
Francis Willard Sarena Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,750
+40.57%
|
-
|
|
Jan 30
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
5,714,285
+22.61%
|
$45,714,280
$8.75 P/Share
|
Last 12 Months Summary
Buy / Acquisition
6.5M
Shares
From
8
Insiders
| Open market or private purchase | 5.75M shares |
|---|---|
| Grant, award, or other acquisition | 746K shares |
Sell / Disposition
407K
Shares
From
8
Insiders
| Payment of exercise price or tax liability | 67.5K shares |
|---|---|
| Grant, award, or other acquisition | 285K shares |
| Open market or private sale | 54.2K shares |